Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Pàgina 1 des de 1002 resultats
4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present application is a National Phase of International Application No. PCT/EP2005/011304 filed Oct. 20, 2005 and claims priority to German Patent Application No. 10 2004 054 215.5, filed Nov. 10, 2004. The contents of both applications are expressly incorporated herein by reference in their
Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancer
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage filing under 35 U.S.C. .sctn. 371(c), of International Application No. PCT/EP2015/061569, filed on May 26, 2015, which claims foreign priority of U.K. Patent Application No. 1409488.2, filed on May 28, 2014. The entire
Protein tyrosine phosphatase mutations in cancers
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This application incorporates a 502 KB text file named "seqlst00631" created Jul. 22, 2010, which is the sequence listing for this application.
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug
Protein tyrosine phosphatase mutations in cancers
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug discovery, target discovery, clinical testing for cancer.
BACKGROUND OF THE INVENTION
Phosphorylation of tyrosine residues is a central feature of most
Methods for identifying a tyrosine phosphatase abnormality associated with neoplastic disease
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Protein tyrosyl phosphorylation is an important cellular regulatory mechanism. Much work has implicated protein tyrosine kinases (PTKs) in the control of cell proliferation and differentiation. Many PTKs, when mutated and/or captured by retroviruses, can promote
AKT tyrosine 176 phosphorylation cancer biomarker
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF INVENTION
This invention relates to methods and compositions for the diagnosis, classification, and treatment of cancer. More specifically, this invention is a method of identifying cancer using novel protein phosphorylation status.
BACKGROUND OF THE INVENTION
The intracellular tyrosine
Tyrosine kinase receptor antagonists and methods of treatment for breast cancer
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Many tumor cells depend on the activity of tyrosine kinases, which act, among other functions, to depress apoptosis in the cell. The tyrosine kinases are usually overproduced in malignant cells, which contributes to the cell's ability to resist apoptosis. Modulating the
Method for treating cancer using a tyrosine protein kinase inhibitor
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
It is presently known that many human diseases are caused at least in part by proteins present in the cells of the afflicted individual. For example, certain proteins encoded by oncogenes are known to be responsible for the production of cancer in humans.
Included among
Tyrosine-phosphorylated WBP2, a novel cancer target and biomarker
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCE TO RELATED APPLICATION
This application is a national stage filing under 35 U.S.C. .sctn.371 of international application PCT/SG2011/000293, filed Aug. 25, 2011, which was published under PCT Article 21(2) in English, and claims the benefit of Singapore Patent Application No.
Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
The present invention concerns the technical field of the pharmaceutical industry.
In particular, the invention relates to compounds with tyrosine kinase inhibiting activity for use in the treatment of cancer in association with a defined dietetic regimen.
PRIOR ART
Molecularly
Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
The present invention concerns the technical field of the pharmaceutical industry.
In particular, the invention relates to compounds with tyrosine kinase inhibiting activity for use in the treatment of cancer in association with a defined dietetic regimen.
PRIOR ART
Molecularly
Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This application relates to combination therapy for the treatment of cancer using inhibitors of heat shock protein 27 (Hasp 27) and an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) such as erlotinib, or antifolates such as pemetrexed.
BACKGROUND OF THE
Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2011/080083 filed Dec. 26, 2011, claiming priority based on Japanese Patent Application No. 2010-290373 filed Dec. 27, 2010, the contents of all of which are incorporated herein by
Treating cancers associated with overexpression of class I family of receptor tyrosine kinases
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
This invention is directed to treatment of class I family of receptor tyrosine kinases overexpressing cancers.
BACKGROUND OF THE INVENTION
The class I family of receptor tyrosine kinases is described in Reese, M. D., et al, Stem Cells, 15, pages 1-8 (1997), the whole of which is
Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.
The present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
